Literature DB >> 18257806

Elimination of liposomes by different separation principles used in low-density lipoprotein apheresis.

Gerhard Pütz1, Jürgen Eckes, Oliver Schmah, Karl Winkler, Heinrich Wieland.   

Abstract

Clinical success of many therapies is impaired by dose limiting toxicities. Nanoscale particle-based drug delivery systems such as liposomes show unique pharmacokinetic properties and improved toxicity profiles. Liposomes accumulate in tumor tissue, but only a small fraction of a total dose reaches the target site. The overwhelming amount of a given dose is needed only to build up a diffusion gradient for effective accumulation at the target site. In order to find a way to detoxify this predominant fraction after accumulation is completed, the different separation principles used for the apheresis of lipoproteins were evaluated for the extracorporeal elimination of liposomes. Appropriate radiolabeled model liposomes were prepared by extrusion. Separation efficacy, leakage of liposomal content and influence of plasma contact were measured. Membranes with pore sizes between 25 and 400 nm were used to investigate filtration properties of liposomes. Liposomes were precipitated by adding heparin and Ca(2+). Adsorption chromatography was investigated using dextran sulfate, heparin sepharose and functionalized polyacrylamide beads. Membrane filtration allowed the elimination of various liposomes, while precipitation and adsorption were only useful for positively charged liposomes. Leakage of liposomal content was not induced by adsorption, but precipitation induced leakage. Leakage during filtration was dependent on liposomal membrane lipids. Plasma contact reduced precipitation and adsorption efficacy of positively charged liposomes, while filtration properties of liposomes remained unchanged. For extracorporeal elimination of liposomal drug delivery systems, filtration-based techniques are presumably more convenient and versatile than precipitation- or adsorption-based apheresis technologies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18257806     DOI: 10.1111/j.1744-9987.2007.00535.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  2 in total

1.  Kinetic targeting of pegylated liposomal doxorubicin: a new approach to reduce toxicity during chemotherapy (CARL-trial).

Authors:  Jürgen Eckes; Oliver Schmah; Jan W Siebers; Ursula Groh; Stefan Zschiedrich; Beate Rautenberg; Annette Hasenburg; Martin Jansen; Martin J Hug; Karl Winkler; Gerhard Pütz
Journal:  BMC Cancer       Date:  2011-08-04       Impact factor: 4.430

2.  Optimizing Antitumor Efficacy and Adverse Effects of Pegylated Liposomal Doxorubicin by Scheduled Plasmapheresis: Impact of Timing and Dosing.

Authors:  Romeo Ngoune; Christine Contini; Michael M Hoffmann; Dominik von Elverfeldt; Karl Winkler; Gerhard Putz
Journal:  Curr Drug Deliv       Date:  2018       Impact factor: 2.565

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.